Contents:

EXECUTIVE SUMMARY The Facts WHAT IS NSCLC AND HOW DOES IT AFFECT PATIENTS? PATIENT STATISTICS Incidence, Diagnosis Rates and Treatment; Now and in the Future The US Europe Japan Patient Mode The Addressable NSCLC Market Will Increase by 9.8 per cent by 2014 DRUG GROWTH DRIVERS DRUG GROWTH RISKS/DAMPENERS THE NSCLC MARKET GLOBAL NSCLC SALES SPLIT US Market European Market Japanese Market THE PLAYERS Players and Products in 2007 Players and Products in 2014 Curent Treatments SURGERY RADIATION CHEMOTHERAPY Leading Brands Chemotherapy Regimens Current Products' Patent Exposure Novel Targeted Therapies Targeting EGFr Targeting VEGF Current Products' Patent Exposure ANALYSIS OF LEADING BRANDS CHEMOTHERAPY Taxanes Taxol Taxotere Antimetabolites Alimta Gemzar NOVEL TARGETED THERAPIES EGFr Inhibitors Iressa Tarceva VEGF Inhibitor Avastin Sales Forecasts Of Curent Nsc lc Drugs RESEARCH & DEVELO PMENT OF NSCLC DRUGS ANALYSIS OF LATE-PHASE DRUGS CHEMOTHERAPY Taxanes Abraxane Opaxio TARGETED THERAPY EGFr Inhibitors Erbitux IGF-1r Inhibitors Figitumumab Multi-action Inhibitors Aflibercept Nexavar Sutent Tovok Vargatef Zactima Tumour Vascular Disrupting Agents ASA404 VACCINES Lucanix MAGE-A3 Stimuvax Other Phase III Drugs AMG 706 NOV-002 Telcyta GLOBAL SALES FORECASTS OF LATE-PHASE NSCLC DRUGS Model Assumptions ANALYSIS OF PHASE II DRUGS Chemotherapy Eloxatin Ixempra Satraplatin Angiogenesis Inhibitors Recentin Armala ABT-869 Axitinib IMC-1121B Death Receptor Agonists AMG 655 AMG 951 Apomab Mapatumumab Other Classes Bavituximab Enzastaurin OGX-011 Perifosine PF-3512676 Velcade Vaccines IDM-2101 TG 4010 Competitor Rati o Analysis Competitor Ratio Analysis Criteria COMPETITOR RATIO ANALYSIS - PRODUCTS COMPETITOR RATIO ANALYSIS - COMPANIES WINNERS & LOSERS Winners Losers DISCONTINUATION OF NSCLC DRUGS APPENDIX 1: PATIENT MODEL APPENDIX 2: GLO BAL NSCLC DRUGS SALES APPENDIX 3: PHASE TRANSITION PROBABILITY BIBLIOGRAPHY GLOSSARY Acronymns Index of Tables Stages of NSCLC and Survival Rates Male and Female Lung Cancer Incidence Rates (Top Five Countries) Summary of Global NSCLC Patient Population Forecasts in Top Seven Countries (2007E-2014E) Standard NSCLC Therapy Platinum-Based Regimens FDA-Approved Regimens for Advanced NSCLC Doublet Regimens EGFr Expression in Solid Tumours Patent Exposure of Leading Brands Efficacy of Taxotere in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based Chemotherapy Regimen (Intent-to-Treat Analysis) Proposed NSCLC Filings for Avastin Avastin Development Proposed Filings of New Indications for Avastin Global NSCLC Sales of Leading Brands 2007A-2014E (US$ millions) Products In Clinical Development for the Treatment Of NSCLC New Drugs in Late-Phase Development to Treat NSCLC Sales Forecasts of Late-Phase Developmental NSCLC Drugs (US$ million) New Drugs in Phase II Development to Treat NSCLC Axitinib Treatment-Related Adverse Events Key NSCLC Drugs Analysed Summary of Key Companies and Drugs in the NSCLC Market by 2014 NSCLC Drugs Discontinued During Development Summary of US NSCLC Patient Population Forecasts Summary of Europe (Top Five) NSCLC Patient Population Forecasts Summary of Japan NSCLC Patient Population Forecasts Global NSCLC Drugs Sales 2007A-2014E Probability of Launch Index of Charts Schematic of the Lung New Cancer Deaths Estimates (2008)* Tobacco use in the US 1900-2002 Global NSCLC Market by Therapy Class (2007A) Global NSCLC Market by Therapy Class (2014E) Global NSCLC Market by Region (2007A) US NSCLC Major Drugs Sales Split (2007A) European NSCLC Major Drugs Sales Split (2007A) Market Share of NSCLC Players by Sales (2007A) Market Share of NSCLC Players by Sales (2014E) EGFr Signal Transduction in Tumour Cells Angiogenesis is the Formation of New Blood Vessels Agents Targeting the VEGF Pathway Efficacy Parameters in Phase III Trials Taxol NSCLC Sales (2007E-2014E) TAX317 Survival K_M Curves - Taxotere 75mg/m2 vs. Best Supportive Care TAX320 Survival K_M Curves - Taxotere 75mg/m2 vs. Vinorelbine or Ifosfamide Control. Taxotere-Treated Patients as % of Patient Popluation (Top 7) Taxotere NSCLC Sales (2007E-2014E) Alimta NSCLC Sales (2007A-2014E) Gemzar NSCLC Sales (2007E-2014E) Iressa NSCLC Sales (2007A-2014E) Tarceva NSCLC Sales (2007E-2014E) Avastin NSCLC Sales (2007E-2014E) 2008 Survey: Medicines in Development for Cancer Abraxane NSCLC Sales (2011E-2014E) Opaxio NSCLC Sales (2009E-2014E) Erbitux NSCLC Sales (2009E-2014E) Pfizer's NSCLC Clinical Development Programme CP-751,871 NSCLC Sales (2013E-2014E) Aflibercept NSCLC Sales (2012E-2014E) Nexavar NSCLC Sales (2012E-2014E) Sutent NSCLC Phase II Results and Phase III (SUN 1087) Study Design Pfizer's NSCLC Clinical Development Programme Sutent NSCLC Sales (2012E-2014E) Tovok NSCLC Sales (2013E-2014E) Vargatef NSCLC Sales (2013E-2014E) Zactima’s Triple Mechanism of Action Zactima NSCLC Sales (2010E-2014E) ASA404 NSCLC Sales (2012E-2014E) Stimuvax NSCLC Sales (2012E-2014E) Ixabepilone: Preclinical Synergy With Targeted Therapies AZD2171 Mechanism Of Action Efficacy and Pharmacokinetic Profile of AZD2171 Compared to Avastin AZD2171 Dose-Dependent Efficacy in NSCLC Axitinib in First-Line NSCLC Mechanism of Action of HGS-ETR1 PF-3512676 Mechanism of Action Through TLR modulation